Azficel-T

Drug Profile

Azficel-T

Alternative Names: Autologous human fibroblasts - Fibrocell Science; Azfibrocel-T; azficel-T fibroblast suspension; Fibroblast cell therapy - Fibrocell Science; Isolagen therapy; Laviv

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator Isolagen
  • Developer Fibrocell Science
  • Class Cell therapies; Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dysphonia; Periodontal disorders; Scars

Highest Development Phases

  • Marketed Facial-wrinkles
  • Discontinued Dysphonia; Periodontal disorders; Scars

Most Recent Events

  • 07 Jul 2016 Fibrocell Technologies terminates phase II trial in Scars (Restrictive burn scars) in USA (NCT01858753)
  • 29 Jun 2016 Azficel-T is available for divestiture as of 29 Jun 2016. www.fibrocell.com
  • 08 Jun 2016 Discontinued - Phase-II/III for Scars (In adults) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top